Omentin-1 plasma levels and cholesterol metabolism in obese patients with diabetes mellitus typ 1: impact of weight reduction
Abstrakt
Background: Omentin-1 is an anti-inflammatory adipokine produced preferentially by visceral adipose tissue. Plasma levels of omentin-1 are decreased in obesity and other insulin-resistant states.
Insulin resistence contributes to the changes of cholesterol synthesis and absorption as well. The aim of this study was to characterise omentin-1 plasma levels in obese patients with diabetes melltius type 1 during weight reduction, and to elucidate the relationship between cholesterol metabolism and omentin-1.
Methods: Plasma levels of omentin-1 were measured in obese type 1 diabetics (n=14, body mass index )30 kg m-2, age 29-62 years) by enzyme-linked immunosorbent assay (BioVendor). Gas chromatography with flame ionisation detector (Fisons Plc.,) was used to measure squalene and non-cholesterol sterols - markers of cholesterol synthesis and absorption (phase I).
Measurements were repeated after 1 month (phase II; 1 week of fasting in the hospital setting and 3 weeks on a diet containing 150 g saccharides per day) and after 1 year (phase III) on a diet with 225 g saccharides per day. Results: Omentin-1 plasma levels were stable during phases I and II, but significantly increased (P (0.001) during phase III.
Omentin-1 plasma dynamics were significantly associated with plasma levels of high-density lipoprotein (P = 0.005) and triacylglycerols (P = 0.01), as well as with lathosterol (P = 0.03). Conclusion: Omentin-1 plasma levels significantly increased during the weight reduction programme.
Omentin-1 plasma dynamics suggest a close relationship with cholesterol metabolism.